Celcuity (CELC) reported Q2 2025 results with a wider-than-expected EPS loss but revenue in line. Clinical progress in breast cancer trials drives investor optimism despite financial misses.
Sara Hurvitz, co-principal investigator for the trial, said that the data for both combination treatments in the trials are “potentially practice-changing.”
